CNS Pharmaceuticals, Inc.
CNSPHealthcareNASDAQBiotechnology · Last scanned Oct 23, 2026
Scan Results
Daily timeframeCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. Valued at $7.3M, CNSP is a micro-cap name in its sector. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Market Cap
$7.3M
Beta
1.02
P/E (TTM)
—
P/E (Fwd)
-12.74
EPS (TTM)
$-18.73
EPS (Fwd)
$-0.39
ROE
-106.6%
ROA
-58.0%
Cash
$20.0M
Total Debt
$0
Free CF
-$7.9M
52W Change
-39.8%
Annual Financials
Cash vs Debt
Where CNSP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CNSP finished 6.85% above its 150-day moving average ($4.67) and 7.78% above its 200-day moving average ($4.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CNSP overbought or oversold?
At the October 20, 2026 close, CNSP's RSI(14) was 52.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
CNS Pharmaceuticals, Inc. reports $20.0M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$7.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -106.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CNS Pharmaceuticals, Inc. and its sector.